MBX insider buying and SEC filings, explained
MBX Biosciences, Inc. · CIK 1776111
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$526K
Insiders who bought
1
Sold (not marked 10b5-1)
$49K
Planned sales (10b5-1)
$2.7M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Aug 4, 2026 | Sale | Salomon Azoulay (Chief Medical Officer) sold 370 shares at about $65.77 ($24K). Holdings down 3% to 14,399 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 5, 2026 |
| May 8, 2026 | Planned (10b5-1) | Salomon Azoulay (Chief Medical Officer) sold 70,003 shares at about $38.36 ($2.7M), marked as a 10b5-1 plan trade. Holdings down 83% to 14,769 shares. | SEC filing Filed May 11, 2026 |
| May 6, 2026 | Sale | Salomon Azoulay (Chief Medical Officer) sold 231 shares at about $29.54 ($7K). Holdings down 2% to 14,769 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 8, 2026 |
| May 6, 2026 | Sale | P. Kent Hawryluk (CEO and Director) sold 607 shares at about $29.54 ($18K). Holdings down <1% to 727,667 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 8, 2026 |
| Mar 13, 2026 | Purchase (code P) | P. Kent Hawryluk (CEO and Director) bought 18,500 shares indirectly (by trust) at about $28.41 ($526K), reported as a purchase (code P). Holdings by trust up 4% to 486,777 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 16, 2026 |
19 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow MBX in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.